Bibliografia scientifica essenziale sulla Sensibilità Chimica Multipla

1. ACOEM Position Statement. Multiple chemical sensitivities: idiopathic environmental intolerance. American College of Occupational and Environmental Medicine. J Occup Environ Med, 1999;41:940-942.
2. Ashford NA and Miller CS: Chemical Exposures: Low Levels and High Stakes, 2nd edition.Wiley & Sons, New York, 1998.
3. Baines CJ, McKeown-Eyssen GE, Riley N, Cole DE, Marshall L, Loescher B,Baines CJ, McKeown-Eyssen GE, Riley N, Cole DE, Marshall L, Loescher B, Jazmaji V: Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures. Occup Med (Lond). 2004;54:408-18.
4. Bartha L, Baumzweiger W et al.: Multiple Chemical Sensitivity. A 1999 Consensus; 1999, Arch Environ Health, 54: 147-149
5. Bell IR, Amend D, Peterson JM, Schwartz GE, Miller CS: Neuropsychiatric and somatic characteristics of young adults with and without self-reported chemical odor intolerance and chemical sensitivity. Arch Environ Health, 1996;51:9-20.
6. Bell IR, Schwartz GE, Baldwin CM, Hardin EE, Klimas NG, Kline JP et al: Individual intolerance in neural sensitization and the role of context in illness from low-level environmental chemical exposure. Environ Health Perspect, 1997;105 suppl 2:539-547.
7. Caress SM, Steinemann AC: Prevalence of Multiple Chemical Sensitivities: a population-based study in the Southeastern United States. Am J Public Health, 2004;94:746-747.
8. Cullen MR, Pace PE, Redlich CA: The experience of the Yale occupational and environmental medicine clinics with multiple chemical sensitivities, 1986-1991. Toxicol Ind Health, 1992;8:15-19.
9. Cullen MR: The worker with multiple chemical sensitivities: an overview. Occup Med, 1987;2:655-661.
10. Dalton P, Hummel T: Chemosensory function and response in idiopathic environmental intolerance. Occup Med, 2000;15:539-556.
11. Dearman RJ, Kimber I. Cytokine profiling and chemical allergy. Toxicol Appl Pharmacol. 2002 Dec 15;185 (3):228-9
12. Fiedler N, Giardino N, Natelson B, Ottenweller JE, Weisel C, Lioy P, Lehrer Fiedler N, Kipen HM. Controlled exposures to volatile organic compounds in sensitive groups. Ann N Y Acad Sci. 2001 Mar;933:24-37. Review.
13. Greene GJ, Kipen HM. The vomeronasal organ and chemical sensitivity: a hypothesis. Environ Health Perspect. 2002 Aug;110 Suppl 4:655-61. Review.
14. IPCS, Conclusions and recommendations of a workshop on multiple chemical sensitivity. Regul Toxicol Pharmacol, 1996;24:188-189.6
15. Kosta, L: Consensus definition of MCS proposed, The Human Ecologist 84: 10, 1999.
16. Ashford, N.A. and Miller, C.S.: Chemical Exposures; Low Levels and High Stakes. Van Nostrand Reinhold, New York, 1991 and 1998
17. Meggs, W.J.; Neurogenic inflammation and sensitivity to environmental chemicals. Environ. Health Perspect 101: 234-238, 1993
18. Ishikawa, S.: Chemical Sensitivity. Jiritsu Shinkel 29; 3-8, 1994. (in Japanese)
19. Ishikawa, S.: Ophthalmopathy due to environmental contaminants. Nippon Ganka Gakkai Wasshi 100: 417-432, 1996. (in Japanese)
20. Shirakawa, S. Ishikawa, S., Rea, W.J. and Johson, A.R.: Evaluation of the autonomic nervous system response by pupillographical study in the chemical sensitive patient. Environmental Medicine 121-127, 1991.
21. Miyata, M. and Namba, T.: Clinical features of multiple chemical sensitivity. Jiritsu Shinkei 33: 257-260, 1996. (in Japanese)
22. Ishikawa, S.: Indefinite complaints and trace chemical substances: diagnostic criteria for chemical sensitivity. Shinshin Igaku 38: 95-102, 1998. (in Japanese)
23. Ishikawa, S. and Miyata, M.: Special Issue of the Multiple Chemical Sensitivity (MCS). Allergy and Immunology 6: 34-42, 1999. (in Japanese)
24. Chemical sensitivity: Diagnostic Criteria Pamphlet. The Report of the Allergy Research Group of the Prolonged Chronic Disease Comprehensive Research Project, Ministry of Health and Welfare, 1997.
25. Diagnostic criteria for chemical sensitivity. Nippon Iji Shinpo, 1998, 25-29. (in Japanese)
26. Bell, I.R., Schwartz, G.E., Baldwin, C.M. and Hardin, E.E.: Neural sensitization and physiological markers in multiple chemical sensitivity. Regul Toxicol Pharmacol 24: 39-47, 1996.
27. Overstreet, D.H., Miller, C.S. Janowsky, D.S. and Russel, R.W.: Potential animal model of multiple chemical sensitivity with cholinergic sensitivity. Toxicology 29: 119-134, 1996.
28. Shih, D.M., Gu L. Xia Y. et. al. : Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394-287, 1998.
29. Hoeck AD, Pall ML: will vitamin D supplementation ameliorate diseases characterized by chronic inflammation and fatigue? In Medical Hypotheses 76(2):208-13 · October 2010
30. Maes M1, Mihaylova I, Bosmans E.. Not in the mind of neurastenic lazybones but in the cell nucleus : patients with chronic fatigue syndrome have increased production of NF K beta. Neuro Endocrinol Lett. 2007 Aug;28(4):456-62.
31. Chatterjee M. Vitamin D and genomic stability. Mutat Res. 2001 Apr 18;475(1-2):69-87
32. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P.. Inhibition of IL-12 production by 1,25 dihydroxyvitamin D3. Involvement of NF K B dpown regulation in transcriptional repression of the p40 gene. J Clin Invest. 1998 Jan 1;101(1):252-62.
33. Caress S. M.,  Steinemann A. C. review of a two-phase population study of MCS. Environ Health Perspect. 2003 Sep; 111(12): 1490–1497.
34. Arcari Morni, D'Eugenio A, Aufiero F, Bioterapia nutrizionale - Nutrizione e funzioni organiche, pp. 47-57. Red Edizioni 2004.
35. J L Gollan, C Bateman, B H Billing (1976). Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome. Gut 17 (5): 335–340. DOI:10.1136/gut.17.5.335. PMID 1278716.
36. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M (2004). UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cance.. Br J Cancer 91 (4): 678-82. PMID 15280
37. C. de Luca, G. Scordo, E.Cesareo, D. Raskovic, G.Genovesi, L. Korkina, “Idiopathic environmental intolerances (IEI): from molecular epidemiology to molecular medicine,” Indian Journal of Experimental Biology, vol. 48, no. 7, pp. 625–635, 2010.
38. L. Korkina, M. G. Scordo, I. Deeva, E. Cesareo, and C. de Luca, “The chemical defensive system in the pathobiology of idiopathic environment-associated diseases,” Current Drug Metabolism, vol. 10, no. 8, pp. 914–931, 2009.
39. H. M. Kipen and N. Fiedler, “Environmental factors in medically unexplained symptoms and related syndromes: the evidence and the challenge,” Environmental Health Perspectives, vol. 110, supplement 4, pp. 597–599, 2002.
40. L. H. Hetherington and J. M. Battershill, “Review of evidence for a toxicological mechanism of idiopathic environmental intolerance,” Human & Experimental Toxicology, vol. 32, no. 1, pp. 3–17, 2013.
41. S. J. Genuis, “Chemical sensitivity: pathophysiology or pathopsychology?” Clinical Therapeutics, vol. 35, no. 5, pp. 572–577, 2013.
42. G. McKeown-Eyssen, C. Baines, D. E. C. Cole et al., “Casecontrol study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR,” International Journal of Epidemiology, vol. 33, no. 5, pp. 971–978, 2004.
43. D. Caccamo, E. Cesareo, S. Mariani et al., “Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population,” Oxidative Medicine and Cellular Longevity, vol. 2013,Article ID 831969, 9 pages, 2013.
44. Evaluation of genetic polymorphisms in patients with multiple chemical sensitivity. Cui X, Lu X, Hiura M, Oda M, Miyazaki W, Katoh T. PLoS One. 2013 Aug 13;8(8):e73708. doi: 10.1371/journal.pone.0073708. eCollection 2013.
45. C. de Luca, J. C. S. Thai, D. Raskovic et al., “Metabolic and genetic screening of electromagnetic hypersensitive subjects as a feasible tool for diagnostics and intervention,” Mediators of Inflammation, vol. 2014, Article ID 924184, 14 pages, 2014.
46. C. De Luca, M. G. Scordo, E. Cesareo et al., “Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobioticmetabolizing enzymes,” Toxicology and Applied Pharmacology, vol. 248, no. 3, pp. 285–292, 2010.
47. C. de Luca,D. Raskovic, V. Pacifico, J. C. S.Thai, and L. Korkina, “The search for reliable biomarkers of disease in multiple chemical sensitivity and other environmental intolerances,” International Journal of Environmental Research and Public Health, vol. 8, no. 7, pp. 2770–2797, 2011.
48. M. L. Pall, “NMDA sensitization and stimulation by peroxynitrite, nitric oxide, and organic solvents as the mechanism of chemical sensitivity inmultiple chemical sensitivity,”TheFASEB Journal, vol. 16, no. 11, pp. 1407–1417, 2002.
49. Y. Vodovotz, P. K. M. Kim, E. Z. Bagci et al., “Inflammatory modulation of hepatocyte apoptosis by nitric oxide: in vivo,invitro, and in silico studies,” Current Molecular Medicine, vol. 4, no. 7, pp. 753–762, 2004.
50. M. L. Pall and J. D. Satterlee, “Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder,” Annals of the New York Academy of Sciences, vol. 933, pp. 323–329, 2001.
51. M. L. Pall, “Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism,” Environmental Health Perspectives, vol. 111, no. 12, pp. 1461–1464, 2003.
52. L. I. Holla, A. Stejskalova, V. Znojil, and A. Vasku, “Analysis of the inducible nitric oxide synthase gene polymorphisms in Czech patients with atopic diseases,” Clinical & Experimental Allergy, vol. 36, no. 12, pp. 1592–1601, 2006.
53. S. Konno, N. Hizawa, E. Yamaguchi, E. Jinushi, and M. Nishimura, “(CCTTT)𝑛 repeat polymorphism in the NOS2 gene promoter is associated with atopy”, Journal of Allergy and Clinical Immunology, vol. 108, no. 5, pp. 810–814, 2001.
54. J. Batra, T. P. Singh, U. Mabalirajan, A. Sinha, R. Prasad, and B. Ghosh, “Association of inducible nitric oxide synthase with asthma severity, total serum immunoglobulin E and blood eosinophil levels,” Thorax, vol. 62, no. 1, pp. 16–22, 2007.
55. F. M. Gonc¸alves, M. R. Luizon, J. G. Speciali, A. Martins-Oliveira, F. Dach, and J. E. Tanus-Santos, “Interaction among nitric oxide (NO)-related genes in migraine susceptibility,” Molecular and Cellular Biochemistry, vol. 370, no. 1-2, pp. 183– 189, 2012.
56. S. S. Dhillon, L. A. Mastropaolo, R. Murchie et al., “Higher activity of the inducible nitric oxide synthase contributes to very early onset inflammatory bowel disease,” Clinical and Translational Gastroenterology, vol. 5, no. 1, article e46, 2014.
57. Y.Miyamoto, Y. Saito, M. Nakayama et al., “Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a −786T→C mutation associated with coronary spastic angina,” Human Molecular Genetics, vol. 9, no. 18, pp. 2629–2637, 2000.
58. E. Schnakenberg, K.-R. Fabig, M. Stanulla et al., “A crosssectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes,” Environmental Health, vol. 6, article 6, 2007.
59. G. A. Wiesmüller, H. Niggemann, W. Weißbach et al., “Sequence variations in subjects with self-reported multiple chemical sensitivity (sMCS): a case-control study,” Journal of Toxicology and Environmental Health Part A: Current Issues, vol. 71, no. 11-12, pp. 786–794, 2008.
60. N. D. Berg, H. Berg Rasmussen, A. Linneberg et al., “Genetic susceptibility factors for multiple chemical sensitivity revisited,” International Journal of Hygiene and Environmental Health, vol. 213, no. 2, pp. 131–139, 2010.
61. E. Bouzigon, F. Monier, M. Boussaha et al., “Associations between nitric oxide synthase genes and exhaled NO-related phenotypes according to asthma status,” PLoS ONE, vol. 7, no. 5, Article ID e36672, 2012.
62. C. H. Sponton, R. Esposti, C. M. Rodovalho et al., “The presence of theNOS3 gene polymorphism for intron 4 mitigates the beneficial effects of exercise training on ambulatory blood pressure monitoring in adults,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 306, no. 12, pp. H1679–H1691, 2014.
63. T. D. O. S. Mansur, F. M. Gonc¸alves, A. Martins-Oliveira et al., “Inducible nitric oxide synthase haplotype associated with migraine and aura,” Molecular and Cellular Biochemistry, vol.364, no. 1-2, pp. 303–308, 2012.
64. R. Er¨oz, A. Bahadir, S. Dikici, and S. Tasdemir, “Association of endothelial nitric oxide synthase gene polymorphisms (894G/T, -786T/C, G10T) and clinical findings in patients with migraine,” NeuroMolecular Medicine, vol. 16, no. 3, pp. 587–593, 2014.
65. M. Pascual, C. Sanz, M. Isidoro-Garc´ıa et al., “(CCTTT)n polymorphism of  NOS2Ain nasal polyposis and asthma: a casecontrol study,” Journal of Investigational Allergology and Clinical Immunology, vol. 18, no. 4, pp. 239–244, 2008
66. De Luca C, Gugliandolo A, Calabrò C, Currò M, Ientile R, Raskovic D, Korkina L, Caccamo D. “Role of polymorphisms of inducible nitric oxide synthase and endothelial nitric oxide synthase in idiopathic environmental intolerances”, Mediators of Inflammation, Volume 2015, Article ID 245308, 10 pages
67. Sanio M and Karvala K. Indoor air and environmental sensitivity. Suomen Lääkärilehti 13/20117, pp848-854. [Article in Finnish].
68. Gibson PR. 2016. The hidden marginalization of persons with environmental sensitivities. Ecopsychol 8:131-137.
69. Crumpler D. MCS and EHS: An Australian Perspective Ecopsychology. May 2017, ahead of print. https://doi.org/10.1089/eco.2016.0041
70. Belpomme D. Campagnac C, Irigary P. 2015. Reliable disease biomarkers characterizing and identifying electrohypersensitivity and multipla chemical sensitivity as two etiopathogenic aspects of a unique pathologial disorder. Rev Environ Health 30:251-71.
71. Shoemaker RC, Schaller J, Schmidt P. 2005. Mold Warriors: Fighting America's hidden threat. Gateway Press. Baltimore
72. Rossi S and Pitidis A. 2018. Multiple chemical sensitivity: review of the state of the art in epidemiology, diagnosis and future perspetives J Occup Envir med, Publish Ahead of Print
73. doi: 10.1097/JOM.0000000000001215.
74. Documento de consenso 2011. Sensibilidad Quimica multiple. Gobierno de Espana. Ministerio de sanidad politica social e iqualdad.
75. http://www.msc.es/organizacion/sns/planCalidadSNS/pdf/equidad/SQM_documento_de_consenso_30nov2011.pdf
76. http://mspsi.gob.es/organizacion/sns/planCalidadSNS/pdf/equidad/SQM_documento_de_consenso_30nov2011.pdf
77. Pall ML. 2009. Multiple Chemical Sensitivity: Toxicological Questions and Mechanisms (part eight, chapter 92) kirjassa Ballantyne B, Marrs TC, Syversen T, editors. General ad Applied Toxicology, 3rd Edition. New Jersey: Wiley 2009.
78. Hope J. A review of the mecchanisms of injury and treatment approaches for illness resulting from exposure to water-damage buildings, mold, and mycotoxins. 2013. Sci World J. 2013:767482.
79. Fisherman EW, Cohen G. 1973. Chemical intolerance to butylated-hydroxyanisole (BHA) and butylated-hydroxytoulene (BHT) and vascular response as an indicator and monitor of drug intolerance. Ann Allergy. 31:126-33.
80. Dantoft TM, Andersson L. Nordin S, Skovbjerg S. 2015. Chemical intolerance. Curr Rhematol Rev 11:167-84.
81. Ishikawa S, Miyata M, Sakabe K, Chemical sensitivity (CS). 2005. Nihon Rinsho May; 63 Suppl 5: 179-84 [Article in  Japanese].
82. Bessac BF and Jordt S-E. 2008. Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control, physiology (Bethesda) 23:360-370.
83. Löwhagen O. 2015. Diagnosis of asthma - new theories. J Asthma 52:538-44.
84. Hillert L, Javanovic H, Åhs F, Savic I. 2013. Women with mulpiple chemical sensitivity have increased harm avoidance and reduced 5-HT (1A) receptor binding potential in the anterior cinculate and amygdala. PloSOne; 8 (1):e54781. https://doi.org/10.1371/journal.pone.0054781
85. Witthöft M, Rist F, Baller J. 2008 Evidence for a specific link between the personality trait of absorption and idiopathic envinromental intolerance. J Tox Environ health A. 71:795-802.
86. Göthe CJ, Molin C, Nilsson CG. 1995. The environmental somatization syndrome. Psychosom 36:1-11.
87. Straus DC. 2011. The possible role of fungal contamination in sick building syndrome. Front Biosci (Elite Ed) 3:562-80.
88. Shoemaker RC. 2010. Surviving mold: Life in the era of dangerous buildings. Otter bay Books. Baltimore.
89. Shoemaker RC, House D, Ryan JC. 2010. Defining the neurotoxin derived illness chronic ciguatera using markers of chronic system infiammatory disturbances: a case/control study. Neurotoxicol Teratol 2:633-9.
90. Miller CS. 2001. Toxicant-induced loss of tolerance. Addiction 96:115-37.
91. Miller CS. 2001. The compelling anomaly of chimical intolerance. Ann NY Acad Sci 933:1-23.
92. Hausteiner C, Bornschein S, Hansen J, Zilker T, Förstl H. 2005. Self-reported chemical sensitivity in Germany: a popolation-based survey, Int J Hyg Environ Health 208:271-8.
93. Berg ND, Linneberg A Dirksen A, Elberling J. 2008. Prevalence of self-reported symptoms and consequences realted to inhalation of airborne chemicals in a Danish general population. Int Arch Occup Environ Health 81:881-7.
94. Hannuksela M and Haahtela T. 2011. Tuoksuyliherkkyys on todellista. Scent sensitivity is real. Duodecim 127:706-11. [Article in Finnish].
95. Pallasaho P. Prevalence and determinants of respiratory symphoms, asthma, chronic bronchitis and allergic sensitization in Helsinki. FinEsS-tutkimus University of Helsinki 2006, p.40
96. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/pallasaho/prevalent.pdf
97. Genuis SJ. 2010. Sensitivity-related illness: the escalating pandemic of allergy, food intolerance and chemical sensitivity. Sci Total Environ 408:6047-61.
98. Gibson PR, Elms AN-M, Ruding LA. 2003. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity. Envir Health Perspect 111:1498-1504.
99. Millqvist E, Ternesten-Hasséus E, Ståhl A, Bende M. 2005. Change in levels of Nerve Growth Factor in nasal secretions after capsacin inhalation in patients with airway symptoms from scents and chemicals. Environ Helath Perspec 113:849-52.
100. Cullen MR. 1987. Multiple chemical sensitivities: summary and directions for future investigatiors. Occup Med 2:801-4.
101. Bartha L, Baumzweiger W, Buscher DS, Callender T, Dahl KA, Davidoff A, et al. 1999. Multiple chemical sensitivity: a 1999 consensus. Arch Environ Health 4:147-149.
102. Lacour M, Zunder T, Schmidtke K, Vaith P, Scheidt C. 2005. Multiple chemical sensitivity syndrome (MCS)--suggestions for an extension of the U.S. MCS-case definition. Int J Hyg Environ Helath 2008:141-51.
103. AMICA: International congress of Amica, "MCS: therapies and prevention". The Rome resolution. Rome 1-16. January 2015 http://www.infoamica.it/international-congress-mcs-therapies-and-prevention-rome/
104. Miller CS and Prihoda TJ. 1999. The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health 15:370-385.
105. Hojo S, Kumano H, Yoshino, Kakatu K, Ishikawa S. 2003. Application of Quick Environmental Exposure Sensitivity Inventory (QEESI) for Japanese population: study of reliability and validity of the questionnaire. Toxicol Ind Health 19:41-49.
106. Rasimus-Sahari S. Effects of microbial mitochondrotoxins from blood and indoor air on mammalial cells. Väitöskirja. 2016, Helsingin yliopisto, maatalous-metsätieteellinen tiedekunta, elintarvike- ja ympäristötieteiden laitos, Dissertationes Schola Doctoralis Scientiae Circumiectalis, Alimentariae, Biologicae.Universitatis Helsinkiensis - URN:ISSN ISBN:2342-5431,
107. http://helda.helsinki.fi/handle/10138/159395
108. Korkalainen M, Täubel M, Naarala J, Kirjavainen P, Koistinen A,  Hyvärinen  A, et al. 2017. Synergist proinflammatory interactions of microbial toxins and structural componentes characteristic to moisture-damage buildings. Indoor Air 27:13-23.
109. Griffiths DE. 2005. Psi-Screen, an In Vitro Toxicity Test System: Applications in Bioassay of Perfumes and Fragrance Chemicals. ATLA 33:471-486.
110. Ustaa J, Hachemb Y, El-Rifaia O, Bou-Moughlabey Y, Echatay K, Griffiths D et al. 2013. Fragranze chemicals lyral and lilial decrease viability of HaCat cell's by increaing free radical production and lowering intracellular ATP level: Protection by antioxidants. Toxicol In Vitro. 27: 339-348.
111. Yang JL, Weissman L, Bohr VA, Mattson MP. 2008. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair (Amst); 7:1110-20.
112. Pall ML, Anderson J. 2004. The vanilloid receptor as a putative target of diverse chemicals in multiple chemical sensitivity. Arch Environ Health 59:363-375.
113. Szallasi A, Biro T, Szabo T, Modarres S, Petersen M, Klusch A et al. 1999. A non-pungent triprenyl phenol of fungal origin, scutigeral, stimulates the rat dorsal root ganglion neurons via interaction at vanilloid receptors. Br J Pharmacol. 126:1351-8.
114. Pall ML. 2007. Nitric oxide synthase partial uncoupling as a key switching mechanism for the NO/ONOO-cycle. Med Hypoth 69:821-5.
115. Szallasi A e Blumberg PM. 1999. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 51:159-211.
116. Claeson AS, Andersoon L. 2017. Symptoms from masked acrolein exposure suggest altered trigeminal reactivity in chemical intolerance, Neuro Toxicol 60;92-98.
117. Pall ML. 2002. NMDA sensitization and stimulation by peroxynitrite, nitric oxide and organic solvents at the mechanism of chemical sensitivity in multiple chemical sensitivity. FASEB J. 16:1407-17.
118. Millqvist E. 2000. Cough provocation with capsaicin is an objective way to test sensory hyperreactivity in patients with asthma-like symptoms. Allergy 55:546-550.
119. Reuter S, Gupta SC, Chaturvedi MM, and Aggarwal BB. 2010. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 49:1603-16
120. Hodgson E, Goldstein JA. Metabolism of Toxicants Phase I Reactions anf Pharmacogenetics. In: Hodgson E, Smart R.C. Introduction to biochemical toxicoligy 3rd ed. Chapter 5, pp.67-113 (2001).
121. Rose RL, Hodgson E. Adaptation to Toxicants. Chemical and Environmental Factors Affecting Metabolism of Xenobiotics In: Hodgson E, Smat RC. Introduction to biochemical toxicology 3rd ed. Chapter 8, pp. 163-198 (2001).
122. Orriols R, Costa R, Cuberas G, Jacas C, Castell J, Sunyer J. 2009. Brain dysfunction in multiple chemical sensitivity. J Neurol Sci 287:72-78.
123. Chiaravalloti A, Pagani M, Micarelli A, Di Piero B, Genovesi G, Alessandrini M, Schillaci O. 2015. Cortical activity durin olfactory stimulation in multiple chemical sensitivity: a (18) F-FDG PET/CT study. Eur J Nucl Med Mol Imaging 42:733-40.
124. Alessandrini M, Micarelli A, Chiaravalloti A, Bruno E, Danieli R, Pierantozzi M, Genovesi G, Öberg J, Pagani M, Schillaci O. 2016. Involvement of subcortical brain structures during olfactory stimulation in multiple chemical sensitivity. Brain Topog 29:243–252.
125. Viziano A, Micarelli A, Alessandrini M. 2017. Noise sensitivity and hyperacusis in patients affected by multiple chemical sensitivity. Int Arch Occup Environ Health 90:189-196.
126. Micarelli A, Viziano A, Genovesi G, Bruno E, Ottaviani F, Alessandrini M. Lack of controlateral suppression in transient-evoked otoacoustic emissions in multiple chemical sensitivity: a clinical correlation study. 2016 Noise Health 18:143-9.
127. Micarelli A, Viziano A, Bruno E, Alessandrini M. Vestibular impairment in Multiple Chemical Sensitivity: Component analysis findings. 2016. J Vestib Res 26:459-468.
128. Inamdar A, Hossain M, Bernstein AI, Miller GW, Richardson JR, Bennett JW. 2013. Fungal-derived semiochemical 1-octen-3ol disrupts dopamina packaging and causes neurodegeneration, PNAS 110:19561-6.
129. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD. 2015. Structural and functional features of central nervous system lymphatic vessels. Nature 523:337-341.
130. Elberling J, Skov PS, Mosbech H, Holst H, Dirksen A, Johansen JD. 2007. Increased release of histamine in patients with respiratory symptoms related to perfume. Clin Exp Allergy 37:1676-80.
131. Kimata H. 2004. Effect of exposure to volatile organic, compounds on plasma levels ofe neuropeptides, nerve growth factor and histamine in patients with self-reported multiple chemical sensitivity. Int J Hyg Environ Health 207: 159-163.
132. Guengerich FP. 2003. Cytochromes P450. Drugs, and Diseases. Mol Interventions 3:194-204.
133. McKeown-Eyssen B, Baines C, Cole DE, Riley N, Tyndale RF, Marshall L, Jazmaji V. 2004.  Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2, and MTHFR. Int J Epidemiol. 33:971–8.
134. Arnold-Llamosas PA, Arrizabalaga-Clemente P, Bonet-Agusti M, de la Fuente-Brull X. 2006. Multiple chemical sensitivity in sick-building syndrome. Medicina Clinica (Barcellona) 126:774-778.
135. Davidoff AL and Keyl PM. 1996. Symptoms and health status in individuals with multiple chemical sensitivities syndrome from four reported sensitizing exposure and general population comparison group. Arch Environ Health 51:201-213.
136. Hodgson M. 2000. Sick building syndrome. Occup Med 15:571-585.
137. Salin JT, Salkinoja-Salonen M, Salin PJ, Nelo K, Holma T, Ohtonene P, Syrjälä H. 2017. Building-related symptoms are linked to the in vitro toxicity of indoor dust and airborne microbial propagules in schools: A cross-sectional study. Environ Res Apr; 154:234-239.
138. Redlich CA, Sparer J, Cullen MR. 1997. Sick-building syndrome. Lancet 349:1013-6.
139. Ross GH. 1997. Clinical characteristics of chemical sensitivity: an illustrative case history of asthma and MCS. Environ Health Perspect 105:43-441.
140. Welch L. S. and Sokas R. 1992. Development of multiple chemical sensitivity after an outbreak of sick-building syndrome. Toxicology and Industrial Health 8:47-50.
141. Claeson AS, Levin JO, Blomquist G, Sunesson AL. 2002. Volatile metabolites from microorganisms grown on humid building materials and synthetic media. J Envir Monitoring 4:667-672.
142. Lee TG. 2003. Health symptoms caused by molds in a courthouse, Archives of Environmental Health 58:442-446.
143. Mahmoudi M, Gershwin ME. Sick building  syndrome. III. Stachybotrys chartarum. 2000. J Asthma 37:191-198.
144. Straus DC, Cooley JD, Jumper A. 2003. Studies on the role of fungi in sick building syndrome. Arch Environ Health 58:475-478.
145. Valtonen V. Clinical Diagnosis of the Dampness and Mold Hypersensitivity Syndrome: Review of the Literature and Suggest Diangostic Criteria. Front Immunol. eCollection 2017 Aug 10;8:951. doi: 10.3389/fimmu.2017.00951.
146. Tuuminen T and Rinne K. Severe sequelae to mold-related illness as demonstrated in two Finnish cohorts. Frontiers in immunol 2017, Apr 3;8:382. doi: 10.3389/fimmu.2017.00382. eCollection 2017.
147. Pavlov IP. 1920. Conditioned reflexes. Oxford University Press. London/New York.
148. Mikkola R, Andersson MA, Kredics L, Grigoriev PA, Sundell N. and Salkinoja-Salonen MS. 2012. 20-Residue and 11-residue peptaibols from the fungus Trichoderma longibrachiatum are synergistic in forming Na+/K+-permeable channels and adverse action towards mammalian cells. FEBS 279:4172-90.
149. Hetherington LH, Battershill JM. 2013. Review of evidence for a toxicological mechanism of idiopathic environmental intolerance. Hum Exp Toxicol 32:3-17.
150. Das-Munshi J, Rubin GJ, Wessely S. 2006. Multiple chemical sensitivities: A systematic review of provocation studies. J Allerg Clin Pharmacol 118:1257-64.
151. Tran MT, Arendt-Nielsen L, Kupers R, Elberling J. 2013. Multiple chemical sensitivity: on the scent of central sensitization. Int J Hyg Environ Health 216: 202-10.
152. Hofmann SG, Ellard KK, Siegle GJ. 2012. Neurobiological correlates of cognitions in fear and anxiety: a cognitive-neurobiological information-processing model. Cogn Emot 26:282-299.
153. Otto T, Giardino ND. 2001. Pavlovian conditioning of emotional responses to olfactory and contestual stimuli: a potential model for the development and expression of chemical intolerance. Ann N Y Acad Sci 933:291-309.
154. Van den Bergh O, Devriese S, Winters W, Veulesmans H, Nemery B, Eelen P, Van de Woestijne KP. 2001. Acquiring symptoms in response to odors: a learning perspective on multiple chemical sensitivity. Ann N Y  Acad Sci 933:278-90.
155. Meggs WJ, The role of Neurogenic Inflammation in the Chemical Sensitivity. Ecopsychology. May 2017, ahed of print. doi: 10.1089/eco.2016.0045.
156. Andersson L, Claeson AS, Ledin L, Wisting F, Nordin S. 2013. The influence of health-risk perception and distress on reactions to low-level chemical exposure. Front Psychol 2013 Nov 5;4:816. doi: 10.3389/fpsyg.2013.00816. eCollection.
157. Vuokko A, Selinheimo S, Sainio M, Suojalehto H, Järnefelt H, Virtanen M, et al. 2015. Decreased work ability associated to indoor air problems--An intervention (RCT) to promote health behavior. NeuroToxicol 2015;9:59-67.
158. Fox RA and Sampalli T. 2015. Adaptation to low levels of chemical exposure in individuls with multiple chemical sensitivity in a controlled indoor environmental Indoor Built Environmental 24713-721.
159. Sampalli T. Fox RA, Dickson R, Fox J. 2012. Proposed model of integrated care to improve health outcomes for individuals with multimorbidities. Patients Preference and Adherence 6:757-764.
160. Hauge CR, Rasmussen A, Piet J, Bonde JP, Jensen C, Sumbundu A, Skovbjerg S. 2015. Mindfulness-based congitive therapy (MBCT) for multiple chemical sensitivity (MCS): Results from a randomized controlled trial with 1 year follow-up. J Psychosom Res 79:628-634.
161. Rea WJ, Pan Y, Johnson AR. 1991. Clearing of toxic volatile hydrocarbons from humans. Bol Asoc Med P. R. 83:321-324.
162. Rea WJ, Ross GH, Johnson AR, Smiley RE, Fenyes EJ. 1991. Chemical sensitivity in physicians, Bol Asoc Med P. R. 83:383-8.
163. Rea WJ, Ross GH, Johnson AR, Ross GH, Suyama H, Fenyves EJ. 1996. Reduction of Chemical Sensitivity by Means of Heat Depuration, Physical Therapy and Nutritional Supplementation in a Controlled Environment. J Nutr Environ Med. 6:141-148.
164. Edvardsson B, Stenberg B, Bergdahl J, Eriksson N, Lindén G, Widman L. 2008. Medical and social prognoses of non-specific building-related symptoms (Sick Building Syndrome): a follow-up study of patients previously referred to hospiatal. Int Arch Occup Environ Health 81:805-12.
165. Neto AM, Zantut-Wittmann DE. 2016. Abnormalities of thyroid hormone metabolism durin system illness: The Low T3 syndrome in different clinical setting. Int J endocrinol 2016: 2157583. Epub 2016 Oct 10.
166. Peterson SJ, McAninch EA, Bianco AC. Is a Normal THS Synonymous With "Euthyroidism" in Levothyroxine Monotherapy? 2016. J Clin Endocrinol MetabDecember 101:4964-73.
167. Wajner SM, Maia AL. 2012. New insights toward the acute non-thyroidal illness syndrome. Front Endocrinol (Lausanne) 26:3:8.  doi: 10.3389/fendo.2012.00008.
168. eCollection 2012.
169. Anyawu EC, Morad M, Campbell AW. 2004. Metabolism of mycotoxins, intracellular functions of vitamin B12, and neurological manifestations in patients with chronic toxigenic mold exposure. A review. Sci World J 4:736-45.
170. Pall ML. (2007) Explaining ‘Unexplained Illness’: Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others”, 16 Chapter book,   Harrington Park (Haworth) Press, New York.